Angio-oedema as an unusual tolerable side effect of voriconazole therapy

Journal of Medical Microbiology

Volumn 57, Issue 8, 2008, Pages 1028-1031

  Gençer, Serap ^a   Özer, Serdar ^a   Demirhan, Güler ^a   Ak, Öznur ^a   Batirel, Ayşe ^a  

^a DR LUTFI KIRDAR KARTAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; C REACTIVE PROTEIN; CASPOFUNGIN; ITRACONAZOLE; VORICONAZOLE;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE REPORT; CLINICAL ASSESSMENT; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LAMINECTOMY; LOADING DRUG DOSE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANGIOEDEMA; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 50249169457     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.47299-0     Document Type: Article

References (25)

1. Ally, R., Schurmann, D., Kreisel, W., Carois, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J. & the Esophageal Candidiasis Study Group (2001). A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33, 1447-1454.
2. Bates, D. W., Su, L., Yu, D. T., Chertow, G. M., Seger, D. L., Gomes, D. R., Dasbach, E. J. & Platt, R. (2001). Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32, 686-693.
3. Denning, D. W. (1998). Invasive aspergillosis. Clin Infect Dis 26, 781-803.
4. Denning, D. W. & Griffiths, C. E. (2001). Mucocutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 26, 648-653.
5. Denning, D. W. & Stevens, D. A. (1990). Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 12, 1147-1201.
6. Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M. & Lode, H. (2002). Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34, 563-571.
7. Ghannoum, M. A. & Kuhn, D. M. (2002). Voriconazole - better chances for patients with invasive mycoses. Eur J Med Res 7, 242-256.
8. Gunsilius, E., Lass-Florl, C., Mur, E., Gabl, C., Gastl, G. & Petzer, A. L. (1999). Aspergillus osteoarthritis in acute lymphoblastic leukemia. Ann Hematol 78, 529-530.
9. Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J. W., Kern, W. V., Marr, K. A., Ribaud, P. & other authors (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347, 408-415.
10. Johnson, L. B. & Kauffman, C. A. (2003). Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36, 630-637.
11. Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Rinaldi, M. G. & Patterson, T. E. (2000). Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 44, 2865-2868.
12. Kohli, R. & Hadley, S. (2005). Fungal arthritis and osteomyelitis. Infect Dis Clin North Am 19, 831-851.
13. Lazarus, H. M., Blumer, J. L., Yanovicjh, S., Schlamm, H. & Romero, A. (2002). Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 42, 395-402.
14. Mouas, H., Lutsar, I., Dupont, B., Fain, O., Herbrecht, R., Lescure, F. X., Lortholary, O. & the Bone Invasive Aspergillosis Study Group (2005). Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 40, 1141-1147.
15. Murphy, M., Bernard, E. M., Ishimaru, T. & Armstrong, D. (1997). Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 41, 696-698.
16. Perez-Gomez, A., Prieto, A., Torresano, M., Díez, E., Mulero, J., Labiano, I. & Andreu, J. L. (1998). Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 27, 226-244.
17. Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre-Cisneros, J., Just-Nübling, G., Schlamm, H. T., Lutsar, I. & other authors (2003). Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis 36, 1122-1131.
18. Pfaller, M. A., Messer, S. A., Hollis, R. J. & Jones, R. N. (2002). Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillence Program, 2000. Antimicrob Agents Chemother 46, 1032-1037.
19. Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J. & Kleinermans, D. (2002). Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46, 2546-2553.
20. Stevens, D. A., Kan, V. L., Judson, M. A., Morrison, V. A., Dummer, S., Denning, D. W., Bennett, J. E., Walsh, T. J., Patterson, T. F. & Pankey, G. A. (2000). Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30, 696-709.
21. Stratov, I., Korman, T. M. & Johnson, P. D. (2003). Management of Aspergillus osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review. Eur J Clin Microbiol Infect Dis 22, 277-283.
22. Walsh, T. J., Lutsar, I., Driscoll, T., Dupont, B., Roden, M., Ghahramani, P., Hodges, M., Groll, A. H. & Perfect, J. R. (2002a). Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21, 240-248.
23. Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R. & other authors (2002b). Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346, 225-234.
24. Wingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Walshe, L., Bowden, R., Anaissie, E., Hiemenz, J. & Lister, J. (1999). Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29, 1402-1407.
25. Winkelstein, J. A., Marino, M. C., Johnson, R. B., Jr, Boyle, J., Curnutte, J., Gallin, J. I., Malech, H. L., Holland, S. M., Ochs, H. & other authors (2000). Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 79, 155-169.